| INTRODUCTION
Defining the key outcomes of therapeutic interventions and the best way to measure those outcomes is essential for clinical and regulatory decision-making. Due to the complexity of Crohn's disease and the multitude of treatments, a number of different outcomes and outcome measures have been reported in clinical trials including symptom scores, composite disease activity indices and quality of life questionnaires. 1, 2 Decision-making also relies on the availability of good information on the unintended effects (harms) from treatments.
Heterogeneity in reporting of outcomes or measurement instruments within clinical trials may hinder the comparison of results within systematic reviews and inhibit the meaningful interpretation of individual studies. 3 One way to mitigate this problem is the introduction of an agreed minimum set of standardised outcomes, to be measured and reported in all trials for a particular condition, referred to as a core outcome set. 4 There is no core outcome set for Crohn's disease, although a model has been proposed for classifying outcomes for all inflammatory bowel diseases using the World Health
Organisation International Classification of Functioning, Disability and Health (ICF). 5 Recently, the International Consortium for Health
Outcomes Measurement developed a "Standard Set" for inflammatory bowel disease with recommendations for the pragmatic measurement of outcomes in routine care to support benchmarking. 6 Also recently published is a study protocol for the development of a core outcome set for inflammatory bowel disease 7 and a core outcome set for fistulising Crohn's disease, 8 indicating the importance of this research area. Future trial design and core outcome set development for Crohn's disease would benefit from a systematic synthesis of outcome reporting across published clinical trials, incorporating statistical testing and consideration of adverse events.
In this study, we systematically reviewed the literature to extract data on the outcomes and measurement instruments used, and the safety outcomes reported, in randomised clinical trials (RCTs) of treatments for Crohn's disease. Our aims were to explore the extent of heterogeneity among existing trials, to examine time trends in reporting and to generate insights to support future trial design and core outcome set development. Our results extend beyond the recently published literature in this area by including a broader set of interventions, offering statistical testing of time trends in outcome reporting and bringing new evidence on harms reporting in Crohn's disease. 8, 9 2 | ME TH ODS
| Systematic search
We registered review protocols with the International Prospective
Register of Systematic Reviews (PROSPERO) database (CRD420 term "Crohn's disease" and the key word "outcome" were used. See Tables S1 to S4 for detailed search criteria.
| Eligibility criteria and study selection
Randomised control trials of drug therapies (corticosteroids, 5-ASAs, immunosuppressants, biologics and antibiotics), surgery and nondrug therapies (enteral nutrition, complementary and alternative medicine, probiotics and prebiotics) were included, as were RCTs of treatments for complications (strictures, fissures, abscesses and perforations). Eligible trials were conducted in adult patients (aged 18 or over) with Crohn's disease. Studies of inflammatory bowel disease populations were eligible provided outcomes were reported separately for Crohn's disease. Studies had to be published as full text in English.
Duplicates were removed after a complete list of RCTs was generated. Two reviewers (HC and JK) independently assessed the sample of 100 studies against eligibility criteria at the title and abstract screening stages and resolved discrepancies by discussion. A random sample of 100 was selected for review due to time constraints. The sample was generated by assigning each article a number and using a random number generator. There were no issues found when screening the 100 articles and the primary researcher (HC) screened the remaining papers independently. Full copies were obtained of all potentially eligible studies and reassessed against eligibility criteria by the primary researcher (HC). Reference was made to the second reviewer (JK) where needed.
| Data collection
Data were extracted from the studies by the primary researcher. A randomly generated sample of 10 studies were reviewed and data extracted by the primary researcher and the secondary researcher (JK) checked the extraction. No inaccuracies were found in the data extraction of the sample of 10 papers and the primary researcher extracted data from the remaining papers independently. Studies were categorised as induction or maintenance with subcategories of medical vs surgical induction and maintenance of medically induced vs surgically induced remission. RCTs focusing solely on patients with fistulising disease were flagged to identify differences in reported outcomes. Efficacy and safety outcomes were recorded as reported as primary or secondary outcomes, or not specified as either. The efficacy outcomes were categorised in line with the method used by Ma et al 10 as clinical or composite-clinical, endoscopic, histologic, biomarkers and patient-reported outcomes (PROs).
Safety-related outcomes were recorded as primary or secondary outcomes.
Adverse event reporting was recorded in specific categories:
adverse events, serious adverse events, treatment-related adverse A critique of the methodological quality of the studies was unnecessary, as this project did not involve synthesis of outcome data.
| Synthesis of results and analysis
A comprehensive record of efficacy and safety outcomes was generated and organised by outcome type. Our main analysis of efficacy outcomes focused on those designated as primary or secondary endpoints. We adopted a similar approach for safety-related outcomes but also analysed all reported data for adverse events and study withdrawals. Adverse event reporting was considered at two levels of the MedDRA hierarchy: system organ classification (SOC) and higher level group term, the latter of which is considered a clinically relevant grouping of MedDRA preferred terms. 11 Adverse events were grouped by MedDRA higher level group terms and ranked in the order of frequency of reporting. The top 10 ranked higher level group term adverse events were compared by trial type and drug class.
A secondary analysis considered the reporting of outcomes were not specified as primary or secondary endpoints. To mirror the increased focus on the importance of mucosal healing, 12 the number of studies that reported additional endoscopic or histologic outcomes or the faecal calprotectin biomarker was assessed.
The proportion of studies reporting each type of outcome was calculated, by trial type. The results were stratified by into pre-2009
and 2009 onwards and the changes over time in reporting were summarised in matrix form with outcome categories listed in rows and frequency of outcome reporting plotted in greyscale on a time axis. 10 The statistical significance of any changes between time periods in outcome reporting was tested using the chi-squared test (with 1 df, the critical value of chi is 3.84).
The review was reported in line with the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and harms the checklist.
13,14
3 | RESULTS
| Systematic search results
The search identified 9561 unique records ( Figure 1 ) and included 181 RCTs (characteristics in Table S5 ). Induction of remission was the focus of 110 studies: 104 (94.5%) through medical and six (5.5%) through surgical approaches [119] [120] [121] [122] [123] [124] Fistula response and remission were commonly reported in fistula studies (nine (90%) and six (60%), respectively). Overall, 14 (12.7%) induction studies and one (1.4%) maintenance study reported fistula response and 10 (9.1%) induction and two (2.8%) maintenance studies reported fistula remission.
Corticosteroid sparing and corticosteroid-free remission were reported in 11 (10.6%) and eight (7.7%) medical induction studies and three (5.8%) and four (7.7%) maintenance studies of medically induced remission respectively. All studies, with one exception, (3) Utility (1) Quality-adjusted life years (1) Patient-reported outcomes Quality of life (70) Pain ( (2) 16 PROM instruments were used once and are recorded in Table S9 Safety-related outcomes Adverse events (60) Abnormal laboratory or ECG parameters (25) Complications of surgery (2) Death ( ( Table 2 ). The Perianal disease Activity Index was used in four (40%) studies of fistula patients and in one nonfistula study. 36, 64, 91, 94, 120 There were 30 definitions of disease worsening or relapse, or recurrence using the CDAI, many of which required the CDAI to exceed a benchmark level such as 150, 200 or 250, with or without an increase from baseline score (Table S6 ). The need for additional therapy and/or surgery were commonly used to define worsening or relapse of disease.
Studies of penetrating disease most commonly used physician assessments of draining fistulas (50% [9, 90 .0%] or 100% [6, 60%] reduction from baseline) as trial endpoints. Two (20.0%) studies of fistula patients used imaging techniques, MRI and diagnostic ultrasound, to assess response, one in each time period.
64,120
| Endoscopy
The reporting of endoscopic outcomes doubled between the two time periods, from 14.4% to 30.4% of studies ( Figure 2A ). This increase was statistically significant with a chi-squared value of 6.31
(95% confidence level). Endoscopic outcomes were reported in 31% 122,179-181,183,185,187,188,190-,193,195 although many benchmarks were used (Table S7) (Table S8 ). The reporting of histologic outcomes as additional outcomes increased between the time periods from 3.2% of studies to 7.1%, but this is not statistically significant at the 95% confidence level. 179, 189, 190, 194 The use of PROs has increased over Other tools for measuring quality of life included the Short-Form 36 40, 50, 106, 120, 121, 153, 160, 161, 169, 173 and its components, 50, 121, 169 Patient Global Assessments, 48, 91, 179 Adverse events were the most common primary and secondary outcomes, reported in 39 (35.5%) induction and 22 (31%) maintenance studies. The reporting of adverse events as a primary or secondary endpoint was most frequently the totality of adverse events but some studies looked for specific treatment-related adverse events or reported the stopping of treatment due to adverse events. 
| Biomarkers

| Adverse events
| Adverse events by intervention group
Five of the 10 most commonly reported adverse event groups for all therapies were also in the top 10 across all intervention groups (Table 3) . Gastrointestinal signs and symptoms, infections (including anal abscess, post-operative wound infection, urinary tract infection, upper respiratory tract infection and pneumonia) and headaches, the three most common adverse event groups for all trials, were ranked in the top four most reported for all trial subtypes. Gastrointestinal inflammatory conditions (Crohn's disease exacerbation) and gastrointestinal motility and defaecation were also commonly reported across all trial subtypes.
General system disorders, such as fatigue, pain, flushing, oedema, chills, influenza like illness, were commonly reported only in trials of medical induction or maintenance of medically induced remission interventions. Neurological disorders, such as dizziness, dysgeusia, paraesthesia, syncope and somnolence, and epidermal and dermal conditions, such as rash, pruritis, skin disorder, erythema and eczema, were in the list of ten most recorded adverse event groups across all trials, but were only commonly reported in medical induction trials.
Body temperature, specifically pyrexia, was one of the 10 most commonly reported adverse events in induction trials, but not maintenance. Procedural related injuries and complications, such as postoperative ileus, post-procedural haemorrhage, post-procedural complication, infusion-related reaction, anastomic leak and the need for therapeutic procedures and support care, such as surgery, hospitalisation and fistula repair, were only commonly reported in surgical induction and post-operative maintenance trials.
| Adverse events by drug class
Gastrointestinal signs and symptoms, and infections were the only two adverse event groups that were consistently ranked in the 10 most commonly reported across all drug classes (including CAM, dietary and prebiotic/probiotic interventions) ( Table 4) were also in the top five most commonly reported adverse events for immunosuppressives, although each was also commonly reported in other drug classes.
Injuries were the fourth most commonly reported adverse event groups for CAM and prebiotic or probiotic trials. However, with underlying terms including stab wound and road traffic accident, these are likely to be unrelated to the interventions.
Surgical interventions offer a different pattern of adverse events, as shown in Table 3 HLGT reported in equal numbers but only in post-operative maintenance trials: hepatobiliary investigations. (ranked first to third most common), are the fourth most common adverse event for surgical interventions, along with headaches and a number of other adverse event groups (Table 3 ).
| Study withdrawals
Withdrawals were most frequently reported due to adverse events (102, 56.4%) and least frequently for serious adverse events (7, Higher level group terms (HLGTs) reported in equal numbers only in one drug class: 5-ASAs trials: 10 = renal disorders (excl nephropathies); exocrine pancreas conditions. Antibiotic trials: 3 = bacterial infectious disorders. Biologics trials: 7 = toxicology and therapeutic drug monitoring; 10 = administration site reactions. Corticosteroids trials: 5 = lipid metabolism disorders. 7 = endocrine disorders of gonadal function. 9 = coagulopathies and bleeding diatheses (excl. thrombocytopenic); cornification and dystrophic skin disorders. Immunosuppressives trials: 5 = white blood cell disorders. Dietary trials: 3 = procedural related injuries and complications; gastrointestinal haemorrhages NEC. 9 = anaemias nonhaemolytic and marrow depression; lipid analyses; pregnancy, labour, delivery and postpartum conditions; suicidal and self-injurious behaviours NEC; appetite and general nutritional disorders. Prebiotic/probiotic trials: 8 = cutaneous neoplasms benign; central nervous system vascular disorders; depressed mood disorders and disturbances; bronchial disorders (excl. neoplasms); peritoneal and retroperitoneal conditions; miscellaneous and site unspecified neoplasms malignant and unspecified.
correlate closely with objective signs of inflammation or with mucosal healing at endoscopy. 198, 199 The time trends we observed in clini- Stool biomarkers offer potential to reliably measure gut-related inflammation and in recent years faecal calprotectin has become available in routine IBD practice. 203 Uncertainty remains as to its performance properties particularly for measuring small bowel, rather than colonic, disease activity 204 and research continues to explore other stool assays to measure the inflammatory process. 205 Faecal calprotectin was reported as an endpoint in only two trials included in this review. 66, 101 We found a statistically significant increase in the report of endoscopy and histology-based outcome measures over time, albeit they remained at a low level and without emergence of a standardised approach. This heterogeneity likely reflects the current suboptimal psychometric properties of individual measurement tools, both for endoscopic and histologic scoring systems. 206, 207 In addition to the cost and invasiveness of ileocolonoscopy, endoscopy is not able to fully characterise small bowel disease or quantify the overall extent of intestinal inflammation in Crohn's disease. There is a growing body of research on the potential use of quantitative imaging such as CT and MRI, 208 but only one trial included in this review included radiological outcomes. health-related quality of life instruments to tools focusing on individual domains (eg Fatigue Impact Score). The IBD-Q was the most frequently reported PROM in the trials (85% of studies reporting PROMs) and there was a statistically significant increase in its use for measuring outcomes in maintenance studies over the time of the review (from 25.5% to 50.0%). However, it was not developed according to the latest FDA recommendations for product labelling claims. 209 New disease-specific PROMs tools are under development to meet the stringent guidelines and enable PROMs to support future regulatory approvals of licencing for Crohn's disease.
Our review covered data for safety outcomes in clinical trials and we found substantial heterogeneity in reporting, which highlights the challenges in categorising adverse events for a complex, chronic condition with a variable disease course and multisystem manifestations.
Lack of treatment efficacy in Crohn's disease may manifest with a diversity of symptoms, which are difficult to distinguish from genuine treatment side effects. Many of the most commonly reported adverse events, such as gastrointestinal signs and symptoms and gastrointestinal inflammatory conditions may reflect disease course.
Nevertheless, these data demonstrate differences in the adverse event profile of different intervention groups and should support renewed attempts to define disease-and intervention-specific adverse events and to standardise safety outcomes as discrete endpoints. This is an important consideration for future core outcome set developers.
Our results highlight how the reporting of outcomes in trials in fistula patients align with overall reporting. The use of PROMS and safety-related endpoints is common across all trials, regardless of disease type. Clinical response was less commonly measured by CDAI, and more frequently measured by fistula closure and the PDAI.
These three outcome measures were the most commonly used in fistula trials identified by this review, which supports the findings of a recently developed core outcome set for fistulising disease. 8 Biomarker, histology and endoscopy outcomes were rarely used in fistula trials and are not included in the core outcome set either, contrary to the general shift in outcomes reporting in Crohn's disease trials. However, patient reports (eg incontinence and drainage)
were more common endpoints in trials of fistula patients than in nonfistula trials, and their importance is borne out in the core outcome sets, which lists several PROMs to be reported in future trials.
Our review independently supports the key findings of a recently published systematic review of outcomes in Crohn's disease. 9 We confirm heterogeneity in definitions of response and remission and the need for a core outcome set to standardise endpoint definitions.
Both studies identified the use of CDAI as the most popular outcome measurement tool overall and of IBD-Q as the most commonly The use of CDAI as a requirement for trial inclusion in their systematic review reduces the ability of the Ma et al review to assess changes in the use of CDAI. We have been able to include such analysis in our paper, and confirm a statistically significant increase in CDAI100, whereas the use of CDAI overall has remained relatively consistent.
Our study has limitations. Whilst it includes a comprehensive listing of outcomes from available Crohn's disease trials, we cannot account for publication bias. The results would have been strengthened by the consideration of nonrandomised controlled trials and observational studies. In particular, this would help to characterise important longer term harms. We did not assess the validity or reliability of the outcome measures identified in the review, although this would form a part of any core outcome set development process.
Our study confirms the variability that exists in reporting of outcomes in published clinical trials of interventions for Crohn's disease.
These data provide a comprehensive resource to support current efforts 7 to redefine optimal outcomes and measurement tools to be included in future studies of comparative effectiveness.
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